FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1999486585> ?p ?o ?g. }

• W1999486585 endingPage "5792" @default.
• W1999486585 startingPage "5785" @default.
• W1999486585 abstract "Several inactivated influenza vaccine formulations for systemic administration in man are currently available for annual (seasonal) immunization: split virus and subunit (either plain-aqueous, or virosomal, or adjuvanted by MF59). From a literature search covering the period 1978-2009, 33 articles could be identified, which described randomized clinical trials comparing at least two of the four vaccine formulations with respect to serum hemagglutination inhibition (HI) antibody response, local and systemic vaccine reactions and serious adverse events after vaccination, and employing seasonal vaccine components and doses. In total, 9121 vaccinees of all ages, either healthy or with underlying diseases, were involved. Most vaccinees were primed or had been vaccinated in previous years. For immunogenicity, homologous post-vaccination geometric mean HI titers (GMTs) were analyzed by a random effects model for continuous data. Unreported standard deviations (SD) were addressed by imputing assumed SD-values. Age and health state of the vaccinees appeared to have little influence on the outcome. The immunogenicity of split, aqueous and virosomal subunit formulations were similar, with geometric mean ratio values (GMR, quotient of paired GMT-values) varying around one (0.93-1.24). The MF59-adjuvanted subunit vaccine induced, on average, larger antibody titers than the non-adjuvanted vaccine formulations, but the absolute increase was small (GMR-values varying between 1.25 and 1.40). Vaccine reactions were analyzed using a random effects model for binary data. Local and systemic reactogenicity was similar among non-adjuvanted formulations. The adjuvanted subunit formulation was more frequently associated with local reactions than the non-adjuvanted formulations (rate ratio: 2.12, significant). Systemic reactions were similar among all vaccine formulations. The original articles emphasized the mild and transient character of the vaccine reactions and the absence of serious vaccine-related adverse events. This adequate amount of evidence led to the conclusion that all the currently available inactivated influenza vaccine formulations are safe, well tolerated and similarly effective to control seasonal influenza outbreaks across primed populations and age ranges." @default.
• W1999486585 created "2016-06-24" @default.
• W1999486585 creator A5012703449 @default.
• W1999486585 creator A5031412427 @default.
• W1999486585 creator A5035842206 @default.
• W1999486585 creator A5060622173 @default.
• W1999486585 creator A5072280199 @default.
• W1999486585 date "2011-08-01" @default.
• W1999486585 modified "2023-09-26" @default.
• W1999486585 title "Immunogenicity and safety of inactivated influenza vaccines in primed populations: A systematic literature review and meta-analysis" @default.
• W1999486585 cites W139913532 @default.
• W1999486585 cites W1916028187 @default.
• W1999486585 cites W1964137543 @default.
• W1999486585 cites W1965755102 @default.
• W1999486585 cites W1969471820 @default.
• W1999486585 cites W1973552027 @default.
• W1999486585 cites W1975721990 @default.
• W1999486585 cites W1980741538 @default.
• W1999486585 cites W1984855202 @default.
• W1999486585 cites W1991507966 @default.
• W1999486585 cites W1993364921 @default.
• W1999486585 cites W1996373763 @default.
• W1999486585 cites W1996380049 @default.
• W1999486585 cites W2011115629 @default.
• W1999486585 cites W2013112188 @default.
• W1999486585 cites W2013872507 @default.
• W1999486585 cites W2014690629 @default.
• W1999486585 cites W2021101853 @default.
• W1999486585 cites W2033150882 @default.
• W1999486585 cites W2036596307 @default.
• W1999486585 cites W2040143553 @default.
• W1999486585 cites W2047574261 @default.
• W1999486585 cites W2049194973 @default.
• W1999486585 cites W2051066193 @default.
• W1999486585 cites W2052017398 @default.
• W1999486585 cites W2061307630 @default.
• W1999486585 cites W2061826132 @default.
• W1999486585 cites W2070208649 @default.
• W1999486585 cites W2071726327 @default.
• W1999486585 cites W2074553605 @default.
• W1999486585 cites W2075877458 @default.
• W1999486585 cites W2077596405 @default.
• W1999486585 cites W2080447498 @default.
• W1999486585 cites W2083527515 @default.
• W1999486585 cites W2084480062 @default.
• W1999486585 cites W2087786242 @default.
• W1999486585 cites W2090619168 @default.
• W1999486585 cites W2092240421 @default.
• W1999486585 cites W2093142379 @default.
• W1999486585 cites W2100804091 @default.
• W1999486585 cites W2102847984 @default.
• W1999486585 cites W2105379465 @default.
• W1999486585 cites W2105893312 @default.
• W1999486585 cites W2107328434 @default.
• W1999486585 cites W2107587363 @default.
• W1999486585 cites W2128076015 @default.
• W1999486585 cites W2142085552 @default.
• W1999486585 cites W2152799907 @default.
• W1999486585 cites W2164193589 @default.
• W1999486585 cites W279343580 @default.
• W1999486585 cites W4302764566 @default.
• W1999486585 doi "https://doi.org/10.1016/j.vaccine.2011.05.040" @default.
• W1999486585 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21624411" @default.
• W1999486585 hasPublicationYear "2011" @default.
• W1999486585 type Work @default.
• W1999486585 sameAs 1999486585 @default.
• W1999486585 citedByCount "70" @default.
• W1999486585 countsByYear W19994865852012 @default.
• W1999486585 countsByYear W19994865852013 @default.
• W1999486585 countsByYear W19994865852014 @default.
• W1999486585 countsByYear W19994865852015 @default.
• W1999486585 countsByYear W19994865852016 @default.
• W1999486585 countsByYear W19994865852017 @default.
• W1999486585 countsByYear W19994865852018 @default.
• W1999486585 countsByYear W19994865852019 @default.
• W1999486585 countsByYear W19994865852020 @default.
• W1999486585 countsByYear W19994865852021 @default.
• W1999486585 countsByYear W19994865852022 @default.
• W1999486585 crossrefType "journal-article" @default.
• W1999486585 hasAuthorship W1999486585A5012703449 @default.
• W1999486585 hasAuthorship W1999486585A5031412427 @default.
• W1999486585 hasAuthorship W1999486585A5035842206 @default.
• W1999486585 hasAuthorship W1999486585A5060622173 @default.
• W1999486585 hasAuthorship W1999486585A5072280199 @default.
• W1999486585 hasConcept C126322002 @default.
• W1999486585 hasConcept C159047783 @default.
• W1999486585 hasConcept C159654299 @default.
• W1999486585 hasConcept C197934379 @default.
• W1999486585 hasConcept C203014093 @default.
• W1999486585 hasConcept C22070199 @default.
• W1999486585 hasConcept C2522874641 @default.
• W1999486585 hasConcept C2777704310 @default.
• W1999486585 hasConcept C2780689484 @default.
• W1999486585 hasConcept C2780801004 @default.
• W1999486585 hasConcept C2780868878 @default.
• W1999486585 hasConcept C32611913 @default.
• W1999486585 hasConcept C71924100 @default.
• W1999486585 hasConceptScore W1999486585C126322002 @default.

• next